De-escalation approaches in the treatment of women with HER2 positive breast cancer need to be personalized, according to Dr. Carmen Criscitiello, European Institute of Oncology, Milan, Italy. Her comments come on the occasion of the presentation of updated research results at the inaugural ESMO Breast Cancer Congress 2019, May 2-4, 2019, in Berlin, Germany.
